Stichting Radboud University Medical Center
- Address
- lock Available on a paid plan
Neoplasms Research at Stichting Radboud University Medical Center
The Medical Oncology department in Nijmegen is conducting clinical trials in oncology focused on improving care for patients with advanced cancers, especially ovarian cancer and metastatic castration-resistant prostate cancer. These studies are designed to evaluate whether new treatment combinations can extend survival and delay disease progression.
- Testing new immunotherapy combinations for platinum-resistant recurrent ovarian cancer
- Evaluating treatment effectiveness in metastatic castration-resistant prostate cancer
- Comparing active therapy with control treatment to measure survival and disease control
This research reflects a strong focus on personalized cancer treatment and on finding better options for patients with difficult-to-treat malignancies.
Eye Diseases Clinical Research
At Stichting Radboud University Medical Center, trials in ophthalmology are exploring better ways to support recovery after corneal transplantation, including Descemet's Membrane Endothelial Keratoplasty (DMEK). The main goal is to improve transplant success while reducing complications and protecting eye health over the long term.
- Studying immunosuppressive care after corneal transplantation
- Reducing the risk of intraocular pressure elevation and endothelial cell loss
- Improving outcomes for patients undergoing DMEK
This area of research aims to make eye transplant care safer and more effective for patients with corneal disease.
Female Urogenital Diseases and Pregnancy Complications Studies
Clinical trials in reproductive health are examining causes and treatments for unexplained recurrent miscarriages. The research is focused on whether a medicine used early in pregnancy can improve the chance of a live birth for women facing repeated pregnancy loss.
- Investigating treatment options for unexplained recurrent miscarriages
- Assessing whether early pregnancy support can improve live birth rates
- Advancing care for women with complex pregnancy complications
These studies aim to generate clearer evidence for managing a challenging condition in maternal and fetal medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 31 therapeutic areas and 15 of 508 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 439 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 96 by active trials.
lock +95 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +41 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Stichting Radboud University Medical Center
lock Showing 1 of 310 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Phase II | Not Recruiting | Nov 2018 | — |
IMP list
lock Showing 1 of 508 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 20 | Unknown | 2015-07-16 | 2026-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.